第三项急性脑出血强化降压集束化治疗试验(INTERACT3):国际阶梯楔形整群随机对照试验
INTERACT3是在9个中低收入国家和1个高收入国家开展的国际多中心阶梯楔形整群随机对照试验,纳入发病6小时内影像确诊的成人自发性脑出血患者7036例(集束化组3221例、常规治疗组3815例)。集束化方案包括早期强化降压(收缩压目标<140 mmHg)、严格血糖控制(无糖尿病者6.1-7.8 mmol/L、糖尿病者7.8-10.0 mmol/L)、退热治疗(体温目标≤37.5°C)及华法林相关抗凝快速逆转(目标INR<1.5,治疗1小时内)。集束化组6个月mRS评分分布优于常规组(共同OR 0.86,95%CI 0.76-0.97,p=0.015),严重不良事件更少(16.0% vs 20.1%,p=0.0098)。作者认为医院应将此方案纳入临床实践。
要点
- 发病6小时内影像确诊的成人自发性脑出血患者,集束化治疗组6个月功能预后不良可能性低于常规治疗组(共同OR 0.86,95%CI 0.76-0.97,p=0.015)。
- 集束化方案要求收缩压目标<140 mmHg、无糖尿病者血糖目标6.1-7.8 mmol/L、糖尿病者7.8-10.0 mmol/L、体温目标≤37.5°C。
- 华法林相关抗凝异常者需在治疗1小时内将INR逆转至<1.5。
- 集束化组严重不良事件发生率为16.0%,低于常规治疗组的20.1%(p=0.0098)。
- 敏感性分析中,额外校正国家和患者变量后结果一致(OR 0.84,95%CI 0.73-0.97,p=0.017)。
适用人群与场景
- 年龄≥18岁、发病6小时内就诊、影像学确诊的自发性脑出血患者。
- 纳入医院为无相关疾病特异性方案或方案不一致、愿意对连续患者实施集束化治疗、有本地负责人并能提供所需研究数据的医院。
诊断标准与关键阈值
- 收缩压异常者目标值<140 mmHg。
- 无糖尿病患者血糖目标6.1-7.8 mmol/L,糖尿病患者血糖目标7.8-10.0 mmol/L。
- 体温异常者目标体温≤37.5°C。
- 华法林相关抗凝异常者目标INR<1.5,且在治疗1小时内达标。
处置流程与药物剂量
- 第一步:对发病6小时内影像确诊的自发性脑出血患者启动集束化方案。
- 第二步:早期强化降低收缩压,目标<140 mmHg。
- 第三步:对血糖异常者严格血糖控制,无糖尿病者目标6.1-7.8 mmol/L,糖尿病者目标7.8-10.0 mmol/L。
- 第四步:对体温异常者给予退热治疗,目标体温≤37.5°C。
- 第五步:对华法林相关抗凝异常者快速逆转抗凝,目标INR<1.5,且在治疗1小时内完成。
研究设计与关键结果
- 研究类型:国际、多中心、盲法终点、阶梯楔形整群随机对照试验,在巴西、中国、印度、墨西哥、尼日利亚、巴基斯坦、秘鲁、斯里兰卡、越南9个中低收入国家和智利1个高收入国家开展。
- 2017年5月27日至2021年7月8日评估206家医院,144家同意加入并随机分配,22家在开始入组前退出,另1家因未获得监管批准被撤回并删除其入组患者数据。
- 2017年12月12日至2021年12月31日筛查10857例患者,排除3821例;改良意向性治疗人群纳入121家医院的7036例患者,集束化组3221例、常规治疗组3815例,主要结局数据分别有2892例和3363例可用。
- 主要结局:集束化组6个月mRS评分分布显示功能预后不良的可能性低于常规治疗组(共同OR 0.86,95%CI 0.76-0.97,p=0.015)。
- 敏感性分析:额外校正国家和患者变量后结果一致(OR 0.84,95%CI 0.73-0.97,p=0.017)。
- 不良事件:集束化组严重不良事件发生率16.0%,低于常规治疗组的20.1%(p=0.0098)。
证据类型、等级与局限
- 证据类型:国际多中心阶梯楔形整群随机对照试验。
- 局限性:22家医院在开始入组前退出,另1家医院因未获得监管批准被撤回且其入组患者数据被删除。
对床旁实践的改变
- 作者认为,医院应将这一集束化方案纳入临床实践,作为此类严重疾病的积极管理组成部分。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Early control of elevated blood pressure is the most promising treatment for acute intracerebral haemorrhage. We aimed to establish whether implementing a goal-directed care bundle incorporating protocols for early intensive blood pressure lowering and management algorithms for hyperglycaemia, pyrexia, and abnormal anticoagulation, implemented in a hospital setting, could improve outcomes for patients with acute spontaneous intracerebral haemorrhage.
METHODS: We performed a pragmatic, international, multicentre, blinded endpoint, stepped wedge cluster randomised controlled trial at hospitals in nine low-income and middle-income countries (Brazil, China, India, Mexico, Nigeria, Pakistan, Peru, Sri Lanka, and Viet Nam) and one high-income country (Chile). Hospitals were eligible if they had no or inconsistent relevant, disease-specific protocols, and were willing to implement the care bundle to consecutive patients (aged ≥18 years) with imaging-confirmed spontaneous intracerebral haemorrhage presenting within 6 h of the onset of symptoms, had a local champion, and could provide the required study data. Hospitals were centrally randomly allocated using permuted blocks to three sequences of implementation, stratified by country and the projected number of patients to be recruited over the 12 months of the study period. These sequences had four periods that dictated the order in which the hospitals were to switch from the control usual care procedure to the intervention implementation of the care bundle procedure to different clusters of patients in a stepped manner. To avoid contamination, details of the intervention, sequence, and allocation periods were concealed from sites until they had completed the usual care control periods. The care bundle protocol included the early intensive lowering of systolic blood pressure (target <140 mm Hg), strict glucose control (target 6·1-7·8 mmol/L in those without diabetes and 7·8-10·0 mmol/L in those with diabetes), antipyrexia treatment (target body temperature ≤37·5°C), and rapid reversal of warfarin-related anticoagulation (target international normalised ratio <1·5) within 1 h of treatment, in patients where these variables were abnormal. Analyses were performed according to a modified intention-to-treat population with available outcome data (ie, excluding sites that withdrew during the study). The primary outcome was functional recovery, measured with the modified Rankin scale (mRS; range 0 [no symptoms] to 6 [death]) at 6 months by masked research staff, analysed using proportional ordinal logistic regression to assess the distribution in scores on the mRS, with adjustments for cluster (hospital site), group assignment of cluster per period, and time (6-month periods from Dec 12, 2017). This trial is registered at Clinicaltrials.gov (NCT03209258) and the Chinese Clinical Trial Registry (ChiCTR-IOC-17011787) and is completed.
FINDINGS: Between May 27, 2017, and July 8, 2021, 206 hospitals were assessed for eligibility, of which 144 hospitals in ten countries agreed to join and were randomly assigned in the trial, but 22 hospitals withdrew before starting to enrol patients and another hospital was withdrawn and their data on enrolled patients was deleted because regulatory approval was not obtained. Between Dec 12, 2017, and Dec 31, 2021, 10 857 patients were screened but 3821 were excluded. Overall, the modified intention-to-treat population included 7036 patients enrolled at 121 hospitals, with 3221 assigned to the care bundle group and 3815 to the usual care group, with primary outcome data available in 2892 patients in the care bundle group and 3363 patients in the usual care group. The likelihood of a poor functional outcome was lower in the care bundle group (common odds ratio 0·86; 95% CI 0·76-0·97; p=0·015). The favourable shift in mRS scores in the care bundle group was generally consistent across a range of sensitivity analyses that included additional adjustments for country and patient variables (0·84; 0·73-0·97; p=0·017), and with different approaches to the use of multiple imputations for missing data. Patients in the care bundle group had fewer serious adverse events than those in the usual care group (16·0% vs 20·1%; p=0·0098).
INTERPRETATION: Implementation of a care bundle protocol for intensive blood pressure lowering and other management algorithms for physiological control within several hours of the onset of symptoms resulted in improved functional outcome for patients with acute intracerebral haemorrhage. Hospitals should incorporate this approach into clinical practice as part of active management for this serious condition.
FUNDING: Joint Global Health Trials scheme from the Department of Health and Social Care, the Foreign, Commonwealth & Development Office, and the Medical Research Council and Wellcome Trust; West China Hospital; the National Health and Medical Research Council of Australia; Sichuan Credit Pharmaceutic and Takeda China.
参考来源
- Ma L, Hu X, Song L, et al. The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial. Lancet. 2023. PMID: 37245517. doi:10.1016/S0140-6736(23)00806-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。